Welcome to our dedicated page for TherapeuticsMD SEC filings (Ticker: TXMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TherapeuticsMD, Inc. filings document the reporting obligations of a Nevada corporation with Nasdaq-listed common stock and a pharmaceutical royalty business. Current reports on Form 8-K furnish financial results and Regulation FD disclosures tied to license revenue, continuing operations, and the company’s royalty-based operating model.
The company’s proxy materials and related 8-K filings cover annual meeting matters, director elections, advisory compensation votes, auditor ratification, amendments affecting authorized common stock, and vote results. Other filings include auditor-change disclosures, late-filing notices, and formal records addressing governance, reporting controls, capital structure, and public-company compliance.
TherapeuticsMD has transformed into a pharmaceutical royalty company after the December 30, 2022 Mayne Transaction that generated $140.0 million in cash plus approximately $12.1 million for net working capital and $1.0 million in prepaid royalties. Under the Mayne License Agreement Mayne Pharma pays royalties of 8.0% on the first $80.0 million of U.S. annual net sales and 7.5% thereafter, with a $3.0 million minimum annual royalty for 12 years (adjusted 3% annually) and a 20-year royalty term.
For the quarter ended June 30, 2025 TherapeuticsMD reported $952 thousand of license revenue (up from $234 thousand a year earlier) and net income of $551 thousand or $0.05 per share. Cash totaled $6.069 million and royalty receivables were $3.743 million (short-term) and $14.840 million (long-term). The company discloses concentration (100% of license revenue from Mayne, Theramex and Knight), ongoing disputes with Mayne Pharma over net working capital and indemnification that gave rise to litigation, and states substantial doubt about its ability to continue as a going concern for the next twelve months.
TherapeuticsMD, Inc. disclosed that it has issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this Current Report and is incorporated by reference into Item 2.02 via Item 7.01. The filing makes clear the material in Item 7.01 and Exhibit 99.1 is furnished, not filed under the Exchange Act and includes an explicit disclaimer that the company has no obligation to publicly update any forward-looking statements. The report lists the press release and an Inline XBRL cover page as exhibits.